Electrolyte disturbances and acute kidney injury induced by imatinib therapy

Imatinib mesylate is an anticancer agent that selectively inhibits protein kinases involved in the pathophysiology of cancer. It is now the first-line therapy for patients with chronic myeloid leukaemia (CML) and is generally well tolerated. Here, we describe a case of a patient receiving imatinib f...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Rodrigo Azevedo, Marques, Igor Denizarde Bacelar, Seguro, Antonio Carlos, Andrade, Lúcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421484/
https://www.ncbi.nlm.nih.gov/pubmed/25949279
http://dx.doi.org/10.1093/ndtplus/sfn188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421484/
https://www.ncbi.nlm.nih.gov/pubmed/25949279
http://dx.doi.org/10.1093/ndtplus/sfn188

Ejemplares similares